StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research note released on Sunday. The brokerage issued a sell rating on the stock.

A number of other analysts also recently weighed in on OCX. Stephens reiterated an equal weight rating and set a $4.00 target price on shares of OncoCyte in a research report on Wednesday, April 17th. Benchmark reiterated a speculative buy rating and set a $5.00 price objective on shares of OncoCyte in a research note on Monday, April 15th. Finally, Needham & Company LLC restated a buy rating and issued a $4.25 target price on shares of OncoCyte in a research report on Thursday, May 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $4.06.

OncoCyte Stock Up 6.3 %

OCX opened at $3.05 on Friday. The firm’s fifty day simple moving average is $2.95 and its 200 day simple moving average is $2.92. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) earnings per share (EPS) for the quarter. The company had revenue of $0.18 million for the quarter. OncoCyte had a negative return on equity of 135.45% and a negative net margin of 2,905.14%. On average, research analysts predict that OncoCyte will post -2.58 earnings per share for the current year.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.